Open Nav

Caribou Biosciences

Raise awareness of Caribou's progress as a therapeutics company

  • Date:Thursday, October 18
  • Time:9:45 AM - 10:00 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Caribou Biosciences is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. We are using a next-generation gene editing technology to develop a pipeline of off-the-shelf CAR-T cell therapies for the treatment of cancer. We are also using gene editing to develop novel microbiome-based therapies. Caribou’s tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. The company is located in Berkeley, California.
  • Company Website:
  • Company HQ City:Berkeley
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Rachel Haurwitz, President and CEO
  • Year Founded:2011
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development :CB010
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :3
  • Additional Information/Comments:Caribou has developed a next generation gene editing technology with higher specificity than the original CRISPR-Cas9 technology. It is now using this next generation technology to build a portfolio of therapeutics.
  • Previous and Current Investors:F-Prime Capital, Anterra, Novartis, Maverick
  • Size of Last Investment Round:$30M
  • Total Amount Raised to Date, In All Rounds:$41.5M
Timothy Herpin
Caribou Biosciences